Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

36.41
+0.86002.42%
Post-market: 36.410.00000.00%19:14 EST
Volume:653.56K
Turnover:23.55M
Market Cap:2.08B
PE:53.18
High:36.61
Open:35.20
Low:34.66
Close:35.55
52wk High:38.69
52wk Low:5.35
Shares:57.12M
Float Shares:38.09M
Volume Ratio:0.88
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6847
EPS(LYR):-1.6475
ROE:15.02%
ROA:5.20%
PB:6.75
PE(LYR):-22.10

Loading ...

BRIEF-Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen

Reuters
·
Jan 12

Stoke Therapeutics Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen

Reuters
·
Jan 12

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout From the Emperor Study of Zorevunersen for the Treatment of Dravet Syndrome

THOMSON REUTERS
·
Jan 12

Stoke Therapeutics Inc: Expects to Complete Enrollment of 150 Patients in Q2 2026, With a Phase 3 Data Readout in Mid-2027

THOMSON REUTERS
·
Jan 12

Stoke Therapeutics Inc - Continues to Explore Potential for Expedited Development, Registration and Delivery of Zorevunersen to Patients

THOMSON REUTERS
·
Jan 12

Stoke Therapeutics Inc : Canaccord Genuity Raises Target Price to $36 From $28

THOMSON REUTERS
·
Jan 05

Stoke Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Dec 17, 2025

Stoke Therapeutics Inc : H.c. Wainwright Raises Target Price to $50 From $35

THOMSON REUTERS
·
Dec 15, 2025

Stoke Therapeutics Director Edward M. Kaye MD Reports Sale of Common Shares

Reuters
·
Dec 11, 2025

Stoke Therapeutics (STOK): Reassessing Valuation After New Zorevunersen Data at the 2025 AES Meeting

Simply Wall St.
·
Dec 08, 2025

BRIEF-Biogen And Stoke Therapeutics Present Data That Further Support The Disease-Modifying Potential Of Zorevunersen

Reuters
·
Dec 05, 2025

Biogen Unveils Promising Clinical Data for Zorevunersen in Dravet Syndrome Treatment

Reuters
·
Dec 05, 2025

Stoke Therapeutics and Biogen Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

THOMSON REUTERS
·
Dec 05, 2025

Stoke Therapeutics Reports Zorevunersen Shows Disease-Modifying Effects in Dravet Syndrome Study

Reuters
·
Dec 01, 2025

Stoke Therapeutics Director Adrian R. Krainer Reports Disposal of Common Shares

Reuters
·
Nov 27, 2025

Jefferies Sticks to Their Buy Rating for Stoke Therapeutics (STOK)

TIPRANKS
·
Nov 24, 2025

BRIEF-Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 19, 2025

Director Adrian R. Krainer Reports Sale of Stoke Therapeutics Inc. Common Shares

Reuters
·
Nov 19, 2025

Stoke Therapeutics Grants Stock Options to New Senior VP and Employees

Reuters
·
Nov 19, 2025

Could Endpoint Choices in the EMPEROR Trial Reveal a Strategic Shift for Stoke Therapeutics (STOK)?

Simply Wall St.
·
Nov 18, 2025